



30 April 2024

Sydney, Australia

## Nyrada Commences Walter Reed Traumatic Brain Injury Study

---

### Highlights:

- Walter Reed Army Institute of Research study of NYR-BI03 in traumatic brain injury has commenced and is expected to conclude in 2HCY2024.
- Separately, the first in-human Phase I clinical trial of NYR-BI03 remains on track to commence in 4QCY2024.

---

**Nyrada Inc (ASX:NYR) (“Nyrada or “Company”)**, a drug development company specialising in novel small molecule therapeutics is pleased to announce the commencement of the Walter Reed Army Institute of Research (WRAIR) study of NYR-BI03 in traumatic brain injury (TBI).

The study will assess the effectiveness of NYR-BI03 in a proprietary WRAIR penetrating TBI model which emulates a severe TBI.

As part of this study, test animals will undergo a penetrating TBI procedure and be treated with either NYR-BI03 or a control vehicle. As with the earlier stroke study, [which results were announced on 28 February 2024](#), neuroprotection will be assessed using biomarker and MRI analysis.

The MRI analysis component of this study will be undertaken at UNSW Sydney using their state-of-the-art small animal imaging facility.

Mitochondrial function, a surrogate for overall brain health, will also be assessed as an exploratory endpoint.

**Nyrada CEO James Bonnar commented:** “This is an exciting next step on the journey to assess the efficacy and tolerability of NYR-BI03, Nyrada’s first-in-class secondary brain injury therapy.

“Nyrada is currently targeting NYR-BI03, which brings a novel mechanism of action, as a therapy for both stroke and moderate to severe TBI. Moderate and severe TBI is considered an [orphan indication](#) by the US Food & Drug Administration designating NYR-BI03 as potentially eligible for an accelerated regulatory pathway.”

-ENDS-



## About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small molecule therapies. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a drug to treat brain injury, specifically traumatic brain injury and stroke, and a cholesterol lowering drug. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.*

### Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### Media Enquiries:

Catherine Strong

Morrow Sodali

T: 02 8234 0111

E: [c.strong@morrrowsodali.com](mailto:c.strong@morrrowsodali.com)

## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.